Montreal Neurological Institute Clinical Research Unit

Montreal, Quebec H3A 3B4

0 studies enrolling now · 6 studies all time

What they study most

Alzheimer's Disease, Alzheimer's Disease Dementia, Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment Due to Alzheimer's Disease, Multiple Sclerosis, Relapsing-Remitting, Parkinson's Disease

Studies at this site

• A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age — Running, not enrolling
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease — Stopped early
• Methodology Study of Novel Outcome Measures to Assess Progression of ALS — Completed